Want to see AU:ILA full AI Analyst Report?
ILA Stock Chart & Stats
AU$0.40
<AU$0.01(1.25%)
At close: 4:00 PM EDT
AU$0.40
<AU$0.01(1.25%)
Day’s Range― - ―
52-Week RangeAU$0.18 - AU$0.63
Previous CloseN/A
Volume241.31K
Average Volume (3M)781.24K
Market Cap
AU$115.41M
Enterprise ValueAU$84.40M
Total Cash (Recent Filing)AU$6.87M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta-0.99
Next Earnings
Aug 27, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding295,916,700
10 Day Avg. Volume388,484
30 Day Avg. Volume781,243
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)3.39
Price to Sales (P/S)204.10
P/FCF Ratio-8.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageZero reported debt and materially higher equity provide durable solvency and financial flexibility. For an R&D-intensive biotech, low leverage reduces near-term refinancing pressure, preserving capacity to fund trials and operations across the next several quarters without immediate debt servicing constraints.
Focused Antiviral R&D PipelineA concentrated small-molecule antiviral program (ISLA-101) targeting dengue and Zika gives the company a clear scientific and market focus. Persistent focus on infectious-disease therapeutics supports strategic clarity, partnership appeal, and potential value creation if clinical or regulatory milestones are achieved over the medium term.
Moderating Cash Burn TrendOperating cash outflows remain negative but have modestly improved year-over-year, indicating some cost or spend discipline. That improvement can extend runway and reduce urgency for near-term funding, giving management more time to advance programs or secure non-dilutive partnerships over the coming months.
Bears Say
Sharp Revenue DeclineA roughly 70% YoY revenue drop sharply reduces internal funding capacity and signals weak commercial or milestone timing. Such volatility undermines cash-flow predictability, making multi-quarter planning harder and increasing likelihood of external financing needs that can dilute shareholders or change strategic plans.
Persistent Negative Operating Cash FlowSustained, sizable negative operating cash flow consumes treasury and forces reliance on external capital despite zero debt. Over 2-6 months this elevates execution risk for R&D programs, increases the chance of dilutive financings, and constrains the company’s ability to scale or respond to development setbacks without new funding.
Deep Net Losses And Weak MarginsLarge ongoing net losses and negative margins mean returns on equity are negative and shareholder value is being consumed. Without clear path to improving margins or revenue, losses will likely persist, heightening the probability of repeated funding rounds and dilutive outcomes for long-term investors.
Island Pharmaceuticals Ltd News
ILA FAQ
What was Island Pharmaceuticals Ltd’s price range in the past 12 months?
Island Pharmaceuticals Ltd lowest share price was AU$0.17 and its highest was AU$0.63 in the past 12 months.
What is Island Pharmaceuticals Ltd’s market cap?
Island Pharmaceuticals Ltd’s market cap is AU$115.41M.
When is Island Pharmaceuticals Ltd’s upcoming earnings report date?
Island Pharmaceuticals Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 20 days.
How were Island Pharmaceuticals Ltd’s earnings last quarter?
Island Pharmaceuticals Ltd released its earnings results on Feb 25, 2026. The company reported -AU$0.019 earnings per share for the quarter, missing the consensus estimate of -AU$0.005 by -AU$0.014.
Is Island Pharmaceuticals Ltd overvalued?
According to Wall Street analysts Island Pharmaceuticals Ltd’s price is currently Overvalued.
Does Island Pharmaceuticals Ltd pay dividends?
Island Pharmaceuticals Ltd does not currently pay dividends.
What is Island Pharmaceuticals Ltd’s EPS estimate?
Island Pharmaceuticals Ltd’s EPS estimate is -0.01.
How many shares outstanding does Island Pharmaceuticals Ltd have?
Island Pharmaceuticals Ltd has 295,916,700 shares outstanding.
What happened to Island Pharmaceuticals Ltd’s price movement after its last earnings report?
Island Pharmaceuticals Ltd reported an EPS of -AU$0.019 in its last earnings report, missing expectations of -AU$0.005. Following the earnings report the stock price went up 1.408%.
Which hedge fund is a major shareholder of Island Pharmaceuticals Ltd?
Currently, no hedge funds are holding shares in AU:ILA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Island Pharmaceuticals Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ILA Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
100.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
86.01%
Trailing 12-Months
Company Description
Island Pharmaceuticals Ltd
Island Pharmaceuticals Limited functions as a pharmaceutical enterprise dedicated to drug discovery and repurposing, with a specific focus on creating preventative or therapeutic solutions for viral infections. Its lead therapeutic agent, ISLA-101, is currently under development for both preventing and treating dengue fever and other illnesses transmitted by mosquitoes. The company participates in various strategic collaborations, including a research partnership with Monash University to evaluate known molecules against host targets, and a research and development alliance with Griffith University aimed at screening for active antiviral compounds through a systematic repurposing approach. Additionally, Island Pharmaceuticals has a research agreement with Compounds Australia, providing access to an extensive drug library containing roughly 4,500 molecules for potential drug repurposing and pipeline enhancement. In anticipation of its ISLA-101 Phase II clinical study, the company has also established a cooperative research and development pact with the U.S. Army. Other key agreements include a supply contract with Catalent for the production of Fenretinide softgels for individuals participating in dengue fever trials, and the entitlement to reference the National Cancer Institute's Investigational New Drug (IND) application for ISLA-101. The company, founded in 2017, is based in Camberwell, Australia.
Technical Analysis
Actinogen Medical
―
Paradigm Biopharmaceuticals
―
Immutep Ltd
―
Dimerix Limited
―
Recce Pharmaceuticals Ltd.
―